Investment
Features
FeesSafety
Academy
More
Pluang+

Price manipulation on TONIC led to a $120M exploit on Cronos, prompting a network halt and rollback.

Market News
08 Sep 2026
Blockonomi
View Source
Bearish
Price manipulation on TONIC led to a $120M exploit on Cronos, prompting a network halt and rollback.

An attacker manipulated the price of TONIC on the Tectonic lending protocol, borrowing $120.4 million across nine markets on the Cronos network. Validators halted the network at block 90,907,150 to prevent further losses and restored the chain to block 90,896,188, reversing $111.2 million of the exploit. About $9.19 million had already left the network before the halt and remains unrecovered. Cronos resumed normal operations after a coordinated rollback and is working with partners to reconcile balances, advising users to beware of scams during the recovery process.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
53 minutes ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
1 hour ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
2 hours ago
NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

NVIDIA price target raised to $345 on strong AI chip demand and earnings growth.

BNP Paribas Exane raised NVIDIA's price target from $285 to $345 due to strong demand for its AI chips, signaling potential upside of about 45.6% from the current price. NVIDIA shares have gained about 25% in 2026, driven by growth in AI infrastructu...

Analyst Insights
Bullish
3 hours ago
Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

Bitcoin hits predicted peak of $126K on Oct 6, 2025; next bottom forecasted for Oct 5, 2026 near $86K.

A 4chan post from December 2023 accurately predicted Bitcoin's all-time high of around $126,000 on October 6, 2025, based on a 364-day market cycle pattern. Following the peak, Bitcoin dropped about 52% by mid-2026 but has since recovered to roughly ...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App